Endothelial dysfunction in Coronavirus disease 2019 (COVID-19): Gender and age influences

Froldi G, Dorigo P.

The cytokine storm and COVID-19

Hu B, Huang S, Yin L.

Pneumococcal superinfection in COVID-19 patients: A series of 5 cases

Cucchiari D, Pericàs JM, Riera J, Gumucio R, Md EC, Nicolás D; Hospital Clínic 4H Team.

Endothelial progenitor cells and mesenchymal stem cells to overcome vascular deterioration and cytokine storm in critical patients with COVID-19

Karaahmet F, Kocaman SA.

A Brewing Storm: The Neuropsychological Sequelae of Hyperinflammation due to COVID-19

Cothran TP, Kellman S, Singh S, Beck JS, Powell KJ, Bolton CJ, Tam JW.

Severe COVID-19 and Healthcare Associated Infections on the ICU: Time to Remember the Basics?

Sturdy A, Basarab M, Cotter M, Hager K, Shakespeare D, Shah N, Randall P, Spray D, Arnold A.

Attenuated early inflammatory response in solid organ recipients with COVID-19

Bösch F, Börner N, Kemmner S, Lampert C, Jacob S, Koliogiannis D, Stangl M, Michel S, Kneidinger N, Schneider C, Fischereder M, Irlbeck M, Denk G, Werner J, Angele MK, Guba MO.

The protective rather than prothrombotic fibrinogen in COVID-19 and other inflammatory states

Thachil J.

A Digital Protein Microarray for COVID-19 Cytokine Storm Monitoring

Song Y, Ye Y, Su SH, Stephens A, Cai T, Chung MT, Han M, Newstead MW, Frame D, Singer BH, Kurabayashi K.

Potential contribution of increased soluble IL-2R to lymphopenia in COVID-19 patients

Zhang Y, Wang X, Li X, Xi D, Mao R, Wu X, Cheng S, Sun X, Yi C, Ling Z, Ma L, Ning Q, Fang Y, Sun B, Wu D.

CytoResc - "CytoSorb" Rescue for critically ill patients undergoing the COVID-19 Cytokine Storm: A structured summary of a study protocol for a randomized controlled trial

Stockmann H, Keller T, Büttner S, Jörres A, Kindgen-Milles D, Kunz JV, Leebmann J, Spies C, Träger K, Treskatsch S, Uhrig A, Willam C, Enghard P, Slowinski T; CytoResc Trial Investigators.

Comment on: "To consider varicella-like exanthem associated with COVID-19, virus varicella zoster and virus herpes simplex must be ruled out. Characterization of herpetic lesions in hospitalized COVID-19 patients."

Fernandez-Nieto D, Ortega-Quijano D, Suarez-Valle A, Burgos-Blasco P, Jimenez-Cauhe J, Fernandez-Guarino M.

Characterization of the Inflammatory Response to Severe COVID-19 Illness

McElvaney OJ, McEvoy N, McElvaney OF, Carroll TP, Murphy MP, Dunlea DM, Ní Choileáin O, Clarke J, O'Connor E, Hogan G, Ryan D, Sulaiman I, Gunaratnam C, Branagan P, O'Brien ME, Morgan RK, Costello RW, Hurley K, Walsh S, de Barra E, McNally C, McConkey S, Boland F, Galvin S, Kiernan F, O'Rourke J, Dwyer R, Power M, Geoghegan P, Larkin C, O'Leary RA, Freeman J, Gaffney A, Marsh B, Curley GF, McElvaney NG.

COVID-19 infection on IL-23 inhibition

Wang CJ, Truong AK.

Amelioration of COVID-19 related cytokine storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release syndrome

Hoiland RL, Stukas S, Cooper J, Thiara S, Chen LYC, Biggs CM, Hay K, Lee AYY, Shojania K, Abdulla A, Wellington CL, Sekhon MS.

Age-related decline of de novo T cell responsiveness as a cause of COVID-19 severity

Nicoli F, Solis-Soto MT, Paudel D, Marconi P, Gavioli R, Appay V, Caputo A.

Immune-Inflammatory Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis

Feng X, Li S, Sun Q, Zhu J, Chen B, Xiong M, Cao G.

Neutrophils, Crucial, or Harmful Immune Cells Involved in Coronavirus Infection: A Bioinformatics Study

Hemmat N, Derakhshani A, Bannazadeh Baghi H, Silvestris N, Baradaran B, De Summa S.

Neutrophilia and NETopathy as Key Pathologic Drivers of Progressive Lung Impairment in Patients With COVID-19

Narasaraju T, Tang BM, Herrmann M, Muller S, Chow VTK, Radic M.

COVID-19 Hyperinflammation: What about Neutrophils?

Didangelos A.

Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19

Luo W, Li YX, Jiang LJ, Chen Q, Wang T, Ye DW.

SARS-CoV-2-reactive interferon-γ-producing CD8(+) T cells in patients hospitalized with Coronavirus Disease 2019

Giménez E, Albert E, Torres I, Remigia MJ, Alcaraz MJ, Galindo MJ, Blasco ML, Solano C, Forner MJ, Redón J, Signes-Costa J, Navarro D.

Systemic inflammatory response and thrombosis due to alterations in the gut microbiota in COVID-19

Mönkemüller K, Fry LC, Rickes S.

COVID-19. Immunothrombosis and the gastrointestinal tract

A Cienfuegos J, Almeida Vargas A, S√°nchez Justicia C.

Re-analysis of SARS-CoV-2-infected host cell proteomics time-course data by impact pathway analysis and network analysis: a potential link with inflammatory response

Bock JO, Ortea I.

Targeting innate immunity by blocking CD14: Novel approach to control inflammation and organ dysfunction in COVID-19 illness

Martin TR, Wurfel MM, Zanoni I, Ulevitch R.

Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients

Wang C, Xie J, Zhao L, Fei X, Zhang H, Tan Y, Nie X, Zhou L, Liu Z, Ren Y, Yuan L, Zhang Y, Zhang J, Liang L, Chen X, Liu X, Wang P, Han X, Weng X, Chen Y, Yu T, Zhang X, Cai J, Chen R, Shi Z, Bian X.

Could SARS-CoV-2-Induced Hyperinflammation Magnify the Severity of Coronavirus Disease (CoViD-19) Leading to Acute Respiratory Distress Syndrome?

Girija ASS, Shankar EM, Larsson M.

Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation

Cardone M, Yano M, Rosenberg AS, Puig M.

Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19

Shah A.

Herpes zoster and severe acute herpetic neuralgia as a complication of COVID-19 infection

Shors AR.

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

Saini KS, Lanza C, Romano M, de Azambuja E, Cortes J, de Las Heras B, de Castro J, Lamba Saini M, Loibl S, Curigliano G, Twelves C, Leone M, Patnaik MM.

Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care

Quartuccio L, Sonaglia A, McGonagle D, Fabris M, Peghin M, Pecori D, De Monte A, Bove T, Curcio F, Bassi F, De Vita S, Tascini C.

COVID-19 and the endothelium

Jung F, Krüger-Genge A, Franke RP, Hufert F, Küpper JH.

Nosocomial infections among patients with COVID-19, SARS and MERS: a rapid review and meta-analysis

Zhou Q, Gao Y, Wang X, Liu R, Du P, Wang X, Zhang X, Lu S, Wang Z, Shi Q, Li W, Ma Y, Luo X, Fukuoka T, Ahn HS, Lee MS, Liu E, Chen Y, Luo Z, Yang K; COVID-19 Evidence and Recommendations Working Group.

Serum Cytokine and Chemokine profile in Relation to the Severity of Coronavirus disease 2019 (COVID-19) in China

Chi Y, Ge Y, Wu B, Zhang W, Wu T, Wen T, Liu J, Guo X, Huang C, Jiao Y, Zhu F, Zhu B, Cui L.

Attenuated interferon and pro-inflammatory response in SARS-CoV-2-infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation

Yang D, Chu H, Hou Y, Chai Y, Shuai H, Lee AC, Zhang X, Wang Y, Hu B, Huang X, Yuen TT, Cai JP, Zhou J, Yuan S, Zhang AJ, Chan JF, Yuen KY.

Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients

Xu ZS, Shu T, Kang L, Wu D, Zhou X, Liao BW, Sun XL, Zhou X, Wang YY.

Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities

Mehta P, Porter JC, Manson JJ, Isaacs JD, Openshaw PJM, McInnes IB, Summers C, Chambers RC.

Rationale for targeting Complement in COVID-19

Polycarpou A, Howard M, Farrar CA, Greenlaw R, Fanelli G, Wallis R, Klavinskis LS, Sacks S.

A case series of COVID-19 patients with chronic hepatitis B virus infection

Li Y, Li C, Wang J, Zhu C, Zhu L, Ji F, Liu L, Xu T, Zhang B, Xue L, Yan X, Huang R, Wu C, Yan X.

Management of patients with Hidradenitis Suppurativa during the COVID-19 pandemic

Montero-Vilchez T, Martinez-Lopez A, Salvador-Rodriguez L, Molina-Leyva A, Arias-Santiago S.

Targeting the interleukin-17 pathway to prevent acute respiratory distress syndrome associated with SARS-CoV-2 infection

Wiche Salinas TR, Zheng B, Routy JP, Ancuta P.

Catastrophic acute bilateral lower limbs necrosis associated with COVID-19 as a likely consequence of both vasculitis and coagulopathy

Del Giudice P, Boudoumi D, Le Guen B, Reverte M, Gutnecht J, Lacour JP, Kraemer JP, Motard A, Roa M.

Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?

Huertas A, Montani D, Savale L, Pichon J, Tu L, Parent F, Guignabert C, Humbert M.

Cautious Interpretation of Antiphospholipid Antibodies in COVID-19

Mehta S, Bhandari S, Mehta S.

A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors

Nicolson PL, Welsh JD, Chauhan A, Thomas MR, Kahn ML, Watson SP.

Alpha-1 adrenergic receptor antagonists for preventing acute respiratory distress syndrome and death from cytokine storm syndrome

Vogelstein JT, Powell M, Koenecke A, Xiong R, Fischer N, Huq S, Khalafallah AM, Caffo B, Stuart EA, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S, Bettegowda C, Konig MF, Mensh B, Athey S.

COVID-19 Induced Hepatitis B Virus Reactivation: A Novel Case From the United Arab Emirates

Aldhaleei WA, Alnuaimi A, Bhagavathula AS.

Endotheliitis and Endothelial Dysfunction in Patients with COVID-19: Its Role in Thrombosis and Adverse Outcomes

Mosleh W, Chen K, Pfau SE, Vashist A.

A Putative Role of de-Mono-ADP-Ribosylation of STAT1 by the SARS-CoV-2 Nsp3 Protein in the Cytokine Storm Syndrome of COVID-19

Claverie JM.

COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation

Griffin JH, Lyden P.

"Acute" monoclonal gammopathy in severe COVID-19

Vazzana N, Ognibene S, Dipaola F.

The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection

Pons S, Fodil S, Azoulay E, Zafrani L.

Strategies to Prevent SARS-CoV-2-Mediated Eosinophilic Disease in Association with COVID-19 Vaccination and Infection

Simon HU, Karaulov AV, Bachmann MF.

COVID-19 cytokine storm: The anger of inflammation

Mahmudpour M, Roozbeh J, Keshavarz M, Farrokhi S, Nabipour I.

Bacterial Pneumonia in COVID-19 critically ill patients: a case series

Dudoignon E, Caméléna F, Deniau B, Habay A, Coutrot M, Ressaire Q, Plaud B, Berçot B, Dépret F.

IL-6 combined with CD8+ T cell count early predict in-hospital mortality for patients with COVID-19

Luo M, Liu J, Jiang W, Yue S, Liu H, Wei S.

Herpes Zoster (shingles) complicating the course of COVID19 infection

Elsaie ML, Nada HA.

Revisiting the Protein C Pathway: An Opportunity for Adjunctive Intervention in COVID-19?

Mazzeffi M, Chow JH, Amoroso A, Tanaka K.

Activated macrophages are the main inflammatory cell in COVID-19 interstitial pneumonia infiltrates. Is it possible to show their metabolic activity and thus the grade of inflammatory burden with (18)F-Fluorocholine PET/CT?

Savelli G, Bonacina M, Rizzo A, Zaniboni A.

Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications

Pelaia C, Tinello C, Vatrella A, De Sarro G, Pelaia G.

Factor VIII and Functional Protein C Activity in Critically Ill Patients With Coronavirus Disease 2019: A Case Series

Tabatabai A, Rabin J, Menaker J, Madathil R, Galvagno S, Menne A, Chow JH, Grazioli A, Herr D, Tanaka K, Scalea T, Mazzeffi M.

Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19

Meng X, Ling Y, Zhang L, Zhang Q, Dong P, Zhu T, Lu H.

IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?

Atal S, Fatima Z.

Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts

Wang J, Jiang M, Chen X, Montaner LJ.

Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis

Yamada T, Wakabayashi M, Yamaji T, Chopra N, Mikami T, Miyashita H, Miyashita S.

Author Correction: Complement as a target in COVID-19?

Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, Lambris JD.

Bacterial and fungal infections among patients with SARS-CoV-2 pneumonia

Antinori S, Galimberti L, Milazzo L, Ridolfo AL.

Chronic Inflammation in the Context of Everyday Life: Dietary Changes as Mitigating Factors

Margină D, Ungurianu A, Purdel C, Tsoukalas D, Sarandi E, Thanasoula M, Tekos F, Mesnage R, Kouretas D, Tsatsakis A.

Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients

Erika P, Domenica Z, Paolo I, Luca R, Giulia L, Alessandro D, Marzia N, Giovanni Battista V, Donata G, Andrea V, Andrea M, Sergio B, Chiara T.

Cytokine Storm Induced by SARS-CoV-2

Song P, Li W, Xie J, Hou Y, You C.

Can steroids reverse the severe COVID-19 induced 'cytokine storm'?

Kolilekas L, Loverdos K, Giannakaki S, Vlassi L, Levounets A, Zervas E, Gaga M.

The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging"

Meftahi GH, Jangravi Z, Sahraei H, Bahari Z.

May the Central Nervous System Be Fogged by the Cytokine Storm in COVID-19?: an Appraisal

Balcioglu YH, Yesilkaya UH, Gokcay H, Kirlioglu SS.

SARS-CoV-2 COVID-19 susceptibility and lung inflammatory storm by smoking and vaping

Kaur G, Lungarella G, Rahman I.

Kawasaki disease in a COVID-19-struck region

Stower H.

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort

Pouletty M, Borocco C, Ouldali N, Caseris M, Basmaci R, Lachaume N, Bensaid P, Pichard S, Kouider H, Morelle G, Craiu I, Pondarre C, Deho A, Maroni A, Oualha M, Amoura Z, Haroche J, Chommeloux J, Bajolle F, Beyler C, Bonacorsi S, Carcelain G, Koné-Paut I, Bader-Meunier B, Faye A, Meinzer U, Galeotti C, Melki I.

COVID-19 and flu, a perfect storm

Belongia EA, Osterholm MT.

Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients

Convertino I, Tuccori M, Ferraro S, Valdiserra G, Cappello E, Focosi D, Blandizzi C.

Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection

de Maat S, de Mast Q, Danser AHJ, van de Veerdonk FL, Maas C.

Interleukin-6 as prognosticator in patients with COVID-19: IL-6 and Covid-19

Grifoni E, Valoriani A, Cei F, Lamanna R, Gelli AMG, Ciambotti B, Vannucchi V, Moroni F, Pelagatti L, Tarquini R, Landini G, Vanni S, Masotti L.

Hypersegmented granulocytes and COVID-19 infection

Salib C, Teruya-Feldstein J.

Multi-System Inflammatory Syndrome in Children in Association with COVID-19

Simpson JM, Newburger JW.

Proinflammatory Cytokines in the Olfactory Mucosa Result in COVID-19 Induced Anosmia

Torabi A, Mohammadbagheri E, Akbari Dilmaghani N, Bayat AH, Fathi M, Vakili K, Alizadeh R, Rezaeimirghaed O, Hajiesmaeili M, Ramezani M, Simani L, Aliaghaei A.

SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020

Belot A, Antona D, Renolleau S, Javouhey E, Hentgen V, Angoulvant F, Delacourt C, Iriart X, Ovaert C, Bader-Meunier B, Kone-Paut I, Levy-Bruhl D.

Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome

Uslu S.

D-dimer and C-reactive Protein Blood Levels Over Time Used to Predict Pulmonary Embolism in Two COVID-19 Patients

Becher Y, Goldman L, Schacham N, Gringauz I, Justo D.

Brief annotations on cytokine release syndrome and interleukin-6 therapeutic blockage in SARS-CoV-2/COVID-19

Amezcua-Guerra LM.

How nicotine can inhibit cytokine storm in the lungs and prevent or lessen the severity of COVID-19 infection?

Kloc M, Ghobrial RM, Kubiak JZ.

Immunometabolism: new insights and lessons from antigen-directed cellular immune responses

Ramalho R, Rao M, Zhang C, Agrati C, Ippolito G, Wang FS, Zumla A, Maeurer M.

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

La Rosée F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, Fellhauer M, Henkes M, Kumle B, Russo SG, La Rosée P.

Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients

Bosch-Barrera J, Martin-Castillo B, Buxó M, Brunet J, Encinar JA, Menendez JA.

Azole-Resistant COVID-19-Associated Pulmonary Aspergillosis in an Immunocompetent Host: A Case Report

Meijer EFJ, Dofferhoff ASM, Hoiting O, Buil JB, Meis JF.

A case of Bacillus cereus bacteremia in a COVID-19 patient treated with steroids

Osakwe N.

SARS-CoV-2 infection: The role of cytokines in COVID-19 disease

Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L.

C-reactive protein: a promising biomarker for poor prognosis in COVID-19 infection

Sahu BR, Kishor Kampa R, Padhi A, Panda AK.

Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City

Cheung EW, Zachariah P, Gorelik M, Boneparth A, Kernie SG, Orange JS, Milner JD.

COVID-19 Critical Illness Pathophysiology Driven by Diffuse Pulmonary Thrombi and Pulmonary Endothelial Dysfunction Responsive to Thrombolysis

Poor HD, Ventetuolo CE, Tolbert T, Chun G, Serrao G, Zeidman A, Dangayach NS, Olin J, Kohli-Seth R, Powell CA.

An inflammatory cytokine signature helps predict COVID-19 severity and death

Del Valle DM, Kim-Schulze S, Hsin-Hui H, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz T, Madduri D, Stock A, Marron T, Xie H, Patel MK, van Oekelen O, Rahman A, Kovatch P, Aberg J, Schadt E, Jagannath S, Mazumdar M, Charney A, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S.

Erythrocytes Reveal Complement Activation in Patients with COVID-19

Lam LM, Murphy SJ, Kuri-Cervantes L, Weisman AR, Ittner CAG, Reilly JP, Pampena MB, Betts MR, Wherry EJ, Song WC, Lambris JD, Cines DB, Meyer NJ, Mangalmurti NS.

Cross-sectional IgM and IgG profiles in SARS-CoV-2 infection

Ozturk T, Howell C, Benameur K, Ramonell RP, Cashman K, Pirmohammed S, Bassit L, Roback J, Marconi VC, Schinazi RF, Wharton W, Lee FE, Hu WT.

A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease

Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, Borgert BA, Moreno CA, Solomon BD, Rodriguez-Barraquer I, Lessler J, Salje H, Burke D, Wesolowski A, Cummings DAT.

Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm

Abdulrab S, Al-Maweri S, Halboub E.

Co-infection with an atypical pathogen of COVID-19 in a young

Chen FL, Wang CH, Hung CS, Su YS, Lee WS.

Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab

Gautier-Vargas G, Baldacini C, Benotmane I, Keller N, Perrin P, Moulin B, Caillard S.

Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series

Wang J, Yang Q, Zhang P, Sheng J, Zhou J, Qu T.

Invasive pulmonary aspergillosis in severe COVID-19 pneumonia

Lahmer T, Rasch S, Spinner C, Geisler F, Schmid RM, Huber W.

Can Hypericum perforatum (SJW) prevent cytokine storm in COVID-19 patients?

Masiello P, Novelli M, Beffy P, Menegazzi M.

Selective C-reactive protein (CRP) apheresis for Covid-19 patients suffering from organ damage

Kayser S, Kunze R, Sheriff A.

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, Oltolini C, Castiglioni B, Tassan Din C, Boffini N, Tomelleri A, Farina N, Ruggeri A, Rovere-Querini P, Di Lucca G, Martinenghi S, Scotti R, Tresoldi M, Ciceri F, Landoni G, Zangrillo A, Scarpellini P, Dagna L.

Sample sizes for surveillance of S. aureus transmission to monitor effectiveness and provide feedback on intraoperative infection control including for COVID-19

Dexter F, Ledolter J, Wall RT, Datta S, Loftus RW.

Autoimmune and inflammatory diseases following COVID-19

Galeotti C, Bayry J.

Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19

Palanques-Pastor T, López-Briz E, Poveda Andrés JL.

Neutrophils and Neutrophil Extracellular Traps Drive Necroinflammation in COVID-19

Tomar B, Anders HJ, Desai J, Mulay SR.

Ethnic Disparities in Hospitalisation for COVID-19 in England: The Role of Socioeconomic Factors, Mental Health, and Inflammatory and Pro-inflammatory Factors in a Community-based Cohort Study

Lassale C, Gaye B, Hamer M, Gale CR, David Batty G.

Challenges and countermeasures in the prevention of nosocomial infections of SARS-CoV-2 before resumption of work: implications for the dermatology department

Zhang Y, Wen J, Chen C, Zeng L, Yang L, Huang C, Feng A, Miao X, Alamgir M, Rao B, Li Y, Tao J.

Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19

Dalamaga M, Karampela I, Mantzoros CS.

Gendered effects on inflammation reaction and outcome of COVID-19 patients in Wuhan

Qin L, Li X, Shi J, Yu M, Wang K, Tao Y, Zhou Y, Zhou M, Xu S, Wu B, Yang Z, Zhang C, Yue J, Cheng C, Liu X, Xie M.

Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients

Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J, Chu Y, Feng Y, Wang Q.

Eosinophilic granulomatosis with polyangiitis mimicking COVID-19: a case report

Hashizume H, Sano Y, Furukawa S, Imokawa S.

Terminal complement inhibition dampens the inflammation during COVID-19

Kulasekararaj AG, Lazana I, Large J, Posadas K, Eagleton H, Villajin JL, Zuckerman M, Gandhi S, Marsh JC.

Does the newly observed inflammatory syndrome in children demonstrate a link between uncontrolled neutrophil extracellular traps formation and COVID-19?

Thierry AR.

May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions?

Marasca C, Ruggiero A, Napolitano M, Fabbrocini G, Megna M.

Direct endothelial damage and vasculitis due to SARS-CoV-2 in small bowel submucosa of CoViD-19 patient with diarrhea

Carnevale S, Beretta P, Morbini P.

Interleukin 6 polymorphisms as an indicator of COVID-19 severity in humans

Kirtipal N, Bharadwaj S.

Thromboinflammatory response in SARS-CoV-2 sepsis

Maiese A, Passaro G, Matteis A, Fazio V, Raffaele R, Paolo MD.

Acro-ischemia and COVID-19 infection: clinical and histopathological features

Calv√£o J, Relvas M, Pinho A, Brinca A, Cardoso JC.

Applied Clinical Pharmacology in a Crisis - Interleukin-6 Axis Blockade and COVID-19

Strohbehn GW, Reid PD, Ratain MJ.

Author Correction: Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Merad M, Martin JC.

Javamide-II Inhibits IL-6 without Significant Impact on TNF-alpha and IL-1beta in Macrophage-Like Cells

Park JB, Peters R, Pham Q, Wang TTY.

Vascular Endothelial Growth Factor (VEGF) as a Vital Target for Brain Inflammation during the COVID-19 Outbreak

Yin XX, Zheng XR, Peng W, Wu ML, Mao XY.

''Tociluzumab challenge: A series of cytokine storm therapy experience in hospitalized Covid-19 pneumonia patients''

Borku Uysal B, Ikitimur H, Yavuzer S, Ikitimur B, Uysal H, Islamoglu MS, Ozcan E, Aktepe E, Yavuzer H, Cengiz M.

Malaria and Parasitic Neglected Tropical Diseases: Potential Syndemics with COVID-19?

Gutman JR, Lucchi NW, Cantey PT, Steinhardt LC, Samuels AM, Kamb ML, Kapella BK, McElroy PD, Udhayakumar V, Lindblade KA.

A fatal case of COVID-19 due to metabolic acidosis following dysregulate inflammatory response (cytokine storm)

Chhetri S, Khamis F, Pandak N, Al Khalili H, Said E, Petersen E.

Coronavirus Disease 2019 (COVID-19) Can Masquerade as Acute Postoperative Periprosthetic Joint Infection

Kenanidis E, Kakoulidis P, Anagnostis P, Beletsiotis A, Tsiridis E.

Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis

Huang I, Pranata R.

Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital

Stochino C, Villa S, Zucchi P, Parravicini P, Gori A, Raviglione MC.

Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19

Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Chakraborty C.

Fungal antigenemia in patients with severe Coronavirus disease 2019 (COVID-19): The facts and challenges

Lei Y, Song Y, Shu Y, Zhao Y, Huo X, Wang H, Zeng Y, Yu X, Li X, Ye G, Fang B, Han S, Li R, Liu L.

Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents?

Lai CC, Wang CY, Hsueh PR.

Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of severe COVID-19 patients

Caccamo N, Sullivan LC, Brooks AG, Dieli F.

Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients

Urra JM, Cabrera CM, Porras L, Ródenas I.

Impact of Anti-TNF and Thiopurines medications on the development of COVID-19 in patients with inflammatory bowel disease: A Nationwide VA cohort study

Khan N, Patel D, Xie D, Lewis J, Trivedi C, Yang YX.

COVID-19 and the impact on malaria

Chiodini J.

Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression

Shen L, Wang C, Zhao J, Tang X, Shen Y, Lu M, Ding Z, Huang C, Zhang J, Li S, Lan J, Wong G, Zhu Y.

IL-6: Relevance for immunopathology of SARS-CoV-2

Gubernatorova EO, Gorshkova EA, Polinova AI, Drutskaya MS.

Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors

Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, Zhang P, Liu X, Gao G, Liu F, Jiang Y, Cheng X, Zhu C, Xia Y.

Reply to "Coronaviruses and immunosuppressed patients. The facts during the third epidemic"

Merli M, Perricone G, Lauterio A, Prosperi M, Travi G, Roselli E, Petrò L, De Carlis L, Belli L, Puoti M.

Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment

Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S.

Decreased B cells on admission was associated with prolonged viral RNA shedding from respiratory tract in Coronavirus Disease 2019: a case control study

Hao S, Lian J, Lu Y, Jia H, Hu J, Yu G, Wang X, Xu K, Ni Q, Li Y, Liu J, Zhao H, Zhang X, Yu L, Yu X, Xiang D, Chen Y, Zheng S, Qiu Y, Li L, Liang T, Yang Y, Sheng J.

Is anosmia the price to pay in an immune-induced scorched-earth policy against COVID-19?

Le Bon SD, Horoi M.

Corticosteroids and the hyper-inflammatory phase of the COVID-19 disease

Taboada M, Caruezo V, Naveira A, Atanassoff PG.

Co-infections in people with COVID-19: a systematic review and meta-analysis

Lansbury L, Lim B, Baskaran V, Lim WS.

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A, Premkumar L, Jadi RS, Marrama D, de Silva AM, Frazier A, Carlin AF, Greenbaum JA, Peters B, Krammer F, Smith DM, Crotty S, Sette A.

Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFα antibodies: a case report

Kunisaki R, Tsukiji J, Kudo M.

Cytokine storm in COVID-19 and parthenolide: preclinical evidence

Bahrami M, Kamalinejad M, Latifi SA, Seif F, Dadmehr M.

Increased sFLT1/PlGF ratio in COVID-19: a novel link to Angiotensin II-mediated endothelial dysfunction

Giardini V, Carrer A, Casati M, Contro E, Vergani P, Gambacorti-Passerini C.

Case series of acute arthritis during COVID-19 admission

López-González MD, Peral-Garrido ML, Calabuig I, Tovar-Sugrañes E, Jovani V, Bernabeu P, García-Sevila R, León-Ramírez JM, Moreno-Perez O, Boix V, Gil J, Merino E, Vela P, Andrés M.

Response to: 'Case series of acute arthritis in COVID-19 admission' by López-González et al

Graef ER, Liew JW, Kim AH, Sparks JA.

Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department

Waltuch T, Gill P, Zinns LE, Whitney R, Tokarski J, Tsung JW, Sanders JE.

Defective Anti-oxidant System: An Aggravating Factor for COVID-19 Patients Outcome?

Kassi EN, Papavassiliou KA, Papavassiliou AG.

Silencing of immune activation with methotrexate in patients with COVID-19

Safavi F, Nath A.

Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis

Iddir M, Brito A, Dingeo G, Fernandez Del Campo SS, Samouda H, La Frano MR, Bohn T.

Role of oxidized LDL-induced "trained macrophages" in the pathogenesis of COVID-19 and benefits of pioglitazone: A hypothesis

Erol A.

Survival of COVID-19 patients requires precise immune regulation: The hypothetical immunoprotective role of nicotinic agonists

Allahverdi Khani M, SalehiRad M, Darbeheshti S, Motaghinejad M.

Successful recovery of severe COVID-19 with cytokine storm treating with extracorporeal blood purification

Wang Q, Hu Z.

Are we now observing an increasing number of coinfections between SARS-CoV-2 and other respiratory pathogens?

Sánchez-Duque JA, Orozco-Hernández JP, Marín-Medina DS, Cvetkovic-Vega A, Aveiro-Róbalo TR, Mondragon-Cardona A, Failoc-Rojas VE, Gutiérrez-Ocampo E, Villamizar-Peña R, Henao-Martínez JF, Arteaga-Livias K, Rodríguez-Morales AJ.

Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19

Ni M, Tian FB, Xiang DD, Yu B.

The perplexing question of trained immunity versus adaptive memory in COVID-19

Kerboua KE.

Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis

Zhu J, Pang J, Ji P, Zhong Z, Li H, Li B, Zhang J.

COVID-19 and the immune system

Paces J, Strizova Z, Smrz D, Cerny J.

The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm?

Bellinvia S, Edwards CJ, Schisano M, Banfi P, Fallico M, Murabito P.

Serum IgA, IgM, and IgG responses in COVID-19

Ma H, Zeng W, He H, Zhao D, Jiang D, Zhou P, Cheng L, Li Y, Ma X, Jin T.

Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2

Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C.

Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study

Salvarani C, Bajocchi G, Mancuso P, Galli E, Muratore F, Boiardi L, Catanoso M, Pipitone N, Cassone G, Girolimetto N, Croci S, Cimino L, Gradellini F, Beltrami M, Di Lernia V, Dolci G, Massari M, Marata AM, Costantini M, Giorgi Rossi P.

Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19

Omarjee L, Janin A, Perrot F, Laviolle B, Meilhac O, Mahe G.

COVID-19 and asthma: To have or not to have T2 inflammation makes a difference?

Morais-Almeida M, Bousquet J.

Cytokine Blood Filtration Responses in COVID-19

Al Shareef K, Bakouri M.

Correlation between immune response and self-reported depression during convalescence from COVID-19

Yuan B, Li W, Liu H, Cai X, Song S, Zhao J, Hu X, Li Z, Chen Y, Zhang K, Liu Z, Peng J, Wang C, Wang J, An Y.

COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia?

Maier CL, Truong AD, Auld SC, Polly DM, Tanksley CL, Duncan A.

The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?

McKechnie JL, Blish CA.

Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19

Park A, Iwasaki A.

Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent

Mazzoni A, Salvati L, Maggi L, Capone M, Vanni A, Spinicci M, Mencarini J, Caporale R, Peruzzi B, Antonelli A, Trotta M, Zammarchi L, Ciani L, Gori L, Lazzeri C, Matucci A, Vultaggio A, Rossi O, Almerigogna F, Parronchi P, Fontanari P, Lavorini F, Peris A, Rossolini GM, Bartoloni A, Romagnani S, Liotta F, Annunziato F, Cosmi L.

Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19

Menendez JA.

Multisystem Inflammatory Syndrome in Children during the COVID-19 pandemic: a case series

Chiotos K, Bassiri H, Behrens EM, Blatz AM, Chang J, Diorio C, Fitzgerald JC, Topjian A, John ARO.

Interleukine-1 et blocage du COVID-19

Balavoine JF.

COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients

Chakraborty C, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Agoramoorthy G.

Innate T cells in COVID-19: friend or foe?

van der Heide V.

The case of Complement activation in COVID-19 multiorgan impact

Noris M, Benigni A, Remuzzi G.

The amount of cytokine-release defines different shades of Sars-Cov2 infection

Bindoli S, Felicetti M, Sfriso P, Doria A.

Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19

Gigante A, Aquili A, Farinelli L, Caraffa A, Ronconi G, Enrica Gallenga C, Tetè G, Kritas SK, Conti P.

COVID-19, microangiopathy, hemostatic activation, and complement

Song WC, FitzGerald GA.

Lymphopenia in COVID-19: Therapeutic Opportunities

Fathi N, Rezaei N.

Decline in invasive pneumococcus diseases while combating the COVID-19 pandemic in Taiwan

Tsai JR, Yang CJ, Huang WL, Chen YH.

Mild course of Coronavirus disease 2019 and spontaneous severe acute respiratory syndrome coronavirus 2 clearance in a patient with depleted peripheral blood B-cells due to treatment with rituximab

Fallet B, Kyburz D, Walker UA.

Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases

Tadolini M, Codecasa LR, García-García JM, Blanc FX, Borisov S, Alffenaar JW, Andréjak C, Bachez P, Bart PA, Belilovski E, Cardoso-Landivar J, Centis R, D'Ambrosio L, De Souza-Galvão ML, Dominguez-Castellano A, Dourmane S, Jachym MF, Froissart A, Giacomet V, Goletti D, Grard S, Gualano G, Izadifar A, Le Du D, Royo MM, Mazza-Stalder J, Motta I, Ong CWM, Palmieri F, Rivière F, Rodrigo T, Rossato Silva D, Sánchez-Montalvá A, Saporiti M, Scarpellini P, Schlemmer F, Spanevello A, Sumarokova E,

COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients

Kox M, Frenzel T, Schouten J, van de Veerdonk FL, Koenen HJPM, Pickkers P; , on behalf of the RCI-COVID-19 study group.

C-Reactive Protein Level May Predict the Risk of COVID-19 Aggravation

Wang G, Wu C, Zhang Q, Wu F, Yu B, Lv J, Li Y, Li T, Zhang S, Wu C, Wu G, Zhong Y.

The role of IgA in COVID-19

Xia Chao Y, Rötzschke O, Tan EK.

The preventive strategy for pandemics in the elderly is to collect in advance samples & data to counteract chronic inflammation (inflammaging)

Fuellen G, Liesenfeld O, Kowald A, Barrantes I, Bastian M, Simm A, Jansen L, Tietz-Latza A, Quandt D, Franceschi C, Walter M.

Extracorporeal Hemoadsorption: An Option for COVID-19 Associated Cytokine Storm Syndrome

Napp LC, Bauersachs J.

Immunity-Boosting Spices and the Novel Coronavirus

Elsayed Y, Khan NA.

The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart

Perricone C, Conigliaro P, Ciccacci C, Marcucci E, Cafaro G, Bartoloni E, Perricone R, Novelli G, Borgiani P, Gerli R.

Treating Covid-19 at the Inflection Point

Chatham WW, Cron RQ.

Presenting characteristics, comorbidities, and outcomes of patients coinfected with COVID-19 and Mycoplasma pneumoniae in the USA

Gayam V, Konala VM, Naramala S, Garlapati PR, Merghani MA, Regmi N, Balla M, Adapa S.

COVID-19 and herpes zoster co-infection presenting with trigeminal neuropathy

de Freitas Ferreira ACA, Rom√£o TT, SIlva Macedo Y, Pupe C, Nascimento OJ.

Does nasal screening for Staphylococcus aureus before surgery compromise health care professional safety in the COVID-19 era?

Mayeur N, Berthoumieu P, Charbonneau H.

Covid-19 induced superimposed bacterial infection

Hendaus MA, Jomha FA.

COVID-19: Avoiding a second tragedy in a tuberculosis burdened country

Yadav SR, Kumar R, Gupta N, Ish P, Chakrabarti S, Kumar A.

Herpes zoster might be an indicator for Latent COVID 19 infection

Elsaie ML, Youssef EA, Nada HA.

Moderate to severe hidradenitis suppurativa under systemic therapy during the COVID-19 outbreak

Giulia R, Alice R, Teresa FM, Paolo D, Simone R.

Community-acquired viral respiratory infections amongst hospitalized inpatients during a COVID-19 outbreak in Singapore: co-infection and clinical outcomes

Wee LE, Ko KKK, Ho WQ, Kwek GTC, Tan TT, Wijaya L.

The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system

Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M.

Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes

Togun T, Kampmann B, Stoker NG, Lipman M.

Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?"

Ceccarelli G, Nardi K, Marchesani F.

Different patterns of Influenza A and B detected during early stages of COVID-19 in a university hospital in S√£o Paulo, Brazil

Luna LKS, Perosa DAH, Conte DD, Carvalho JMA, Alves VRG, Cruz JS, Bellei N.

Can Ticagrelor be used to prevent sepsis-induced coagulopathy in COVID-19?

Omarjee L, Meilhac O, Perrot F, Janin A, Mahe G.

SARS-CoV-2 infection-induced immune responses: friends or foes?

Li K, Hao Z, Zhao X, Du J, Zhou Y.

COVID-19, tuberculosis, and poverty: preventing a perfect storm

Saunders MJ, Evans CA.

Pulmonary and systemic involvement of COVID-19 assessed by ultrasound-guided minimally invasive autopsy

Nunes Duarte-Neto A, de Almeida Monteiro RA, da Silva LFF, Malheiros DMAC, de Oliveira EP, Theodoro Filho J, Pinho JRR, Soares Gomes-Gouvêa M, Salles APM, de Oliveira IRS, Mauad T, do Nascimento Saldiva PH, Dolhnikoff M.

Septic shock presentation in adolescents with COVID-19

Dallan C, Romano F, Siebert J, Politi S, Lacroix L, Sahyoun C.

Thymosin alpha 1 (Tα1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells

Liu Y, Pang Y, Hu Z, Wu M, Wang C, Feng Z, Mao C, Tan Y, Liu Y, Chen L, Li M, Wang G, Yuan Z, Diao B, Wu Y, Chen Y.

Pediatric COVID-associated Multi-system Inflammatory Syndrome (PMIS)

Shulman ST.

COVID-19 Associated Pediatric Multi-System Inflammatory Syndrome

Deza Leon MP, Redzepi A, McGrath E, Abdel-Haq N, Shawaqfeh A, Sethuraman U, Tilford B, Chopra T, Arora H, Ang J, Asmar B.

Clostridiodes difficile in COVID-19 Patients, Detroit, Michigan, USA, March-April 2020

Sandhu A, Tillotson G, Polistico J, Salimnia H, Cranis M, Moshos J, Cullen L, Jabbo L, Diebel L, Chopra T.

Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?

Chen G, Zhou Y, Ma J, Xia P, Qin Y, Li X.

COVID-19: The Inflammation Link and the Role of Nutrition in Potential Mitigation

Zabetakis I, Lordan R, Norton C, Tsoupras A.

Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line

A C, A B, L ZDV, A T, F L, M G, F B, M M, R C, S DG.

Complement Activation During Critical Illness: Current Findings and an Outlook in the Era of COVID-19

Bosmann M.

Is the COVID-19 pandemic masking the deadlier Lassa fever epidemic in Nigeria?

Reuben RC, Danladi MMA, Pennap GR.

The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the "cytokine storm" in COVID-19 patients: a hypothesis

Thomas G, Frederick E, Hausburg M, Goldberg L, Hoke M, Roshon M, Mains C, Bar-Or D.

The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection

Kellam P, Barclay W.

The role of interleukin-6 in monitoring severe case of coronavirus disease 2019

Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, Cheng J, Zhang X, Zhao Y, Xia Z, Zhang L, Wu G, Yi J.

Cytokine Storm: Is it the only major death factor in COVID-19 patients? Coagulation role

Magro G.

Generalizability of Deep Learning Tuberculosis Classifier to COVID-19 Chest Radiographs: New Tricks for an Old Algorithm?

Yi PH, Kim TK, Lin CT.

Novel paediatric presentation of COVID-19 with ARDS and cytokine storm syndrome without respiratory symptoms

Pain CE, Felsenstein S, Cleary G, Mayell S, Conrad K, Harave S, Duong P, Sinha I, Porter D, Hedrich CM.

Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy

Wang L, Zhang Y, Zhang S.

An asplenic with life-threatening Capnocytophaga canimorsus sepsis

Wendt R, Schauff C, Lübbert C.

Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care

Quartuccio L, Sonaglia A, McGonagle D, Fabris M, Peghin M, Pecori D, Monte A, Bove T, Curcio F, Bassi F, Vita S, Tascini C.

Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19

Hassoun A, Thottacherry ED, Muklewicz J, Aziz QU, Edwards J.

What does the COVID-19 pandemic mean for HIV, tuberculosis, and malaria control?

Amimo F, Lambert B, Magit A.

Covid-19 accelerates endothelial dysfunction and nitric oxide deficiency

Green SJ.

Association of inflammatory markers with the severity of COVID-19: a meta-analysis

Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, Deng G.

Systemic endothelial dysfunction: a common pathway for COVID-19, cardiovascular and metabolic diseases

De Lorenzo A, Escobar S, Tibiriçá E.

Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes

England JT, Abdulla A, Biggs CM, Lee AYY, Hay KA, Hoiland RL, Wellington CL, Sekhon M, Jamal S, Shojania K, Chen LYC.

Multidrug resistant infections in the COVID-19 era, a framework for considering the potential impact

Donà D, Di Chiara C, Sharland M.

Elevated levels of interleukin-6 and CRP predict the need for mechanical ventilation in COVID-19

Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, Klein M, Weinberger T.

Opportunistic virus infections in psoriasis patients: the safer alternative of apremilast

Armesto S, González Vela C, González López MA.

COVID-19 as an Acute Inflammatory Disease

Manjili RH, Zarei M, Habibi M, Manjili MH.

Type 2 Inflammation Modulates ACE2 and TMPRSS2 in Airway Epithelial Cells

Kimura H, Francisco D, Conway M, Martinez FD, Vercelli D, Polverino F, Billheimer D, Kraft M.

Perforin and resistance to SARS coronavirus 2

Cunningham L, Simmonds P, Kimber I, Basketter DA, McFadden JP.

Cytokine Levels in the Body Fluids of a Patient With COVID-19 and Acute Respiratory Distress Syndrome: A Case Report

Wang C, Kang K, Gao Y, Ye M, Lan X, Li X, Zhao M, Yu K.

Is there relationship between SARS-CoV 2 and the complement C3 and C4?

Dheir H, Sipahi S, Yaylaci S, Köroğlu M, Erdem AF, Karabay O.

SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc

Magro G.

Atypical lymphocytes in peripheral blood of patients with COVID-19.

Weinberg SE, Behdad A, Ji P.

Temporal Changes in Immune Blood Cell Parameters in COVID-19 Infection and Recovery from Severe Infection.

Yip CY, Yap ES, Mel S, Teo WZY, Lee CT, Kan S, Lee CCM, Loh WN, Lim EL, Lee SY.

COVID-19 as a cardiovascular disease: the potential role of chronic endothelial dysfunction.

Bermejo-Martin JF, Almansa R, Torres A, Gonz√°lez-Rivera M, Kelvin DJ.

Clozapine is strongly associated with the risk of pneumonia and inflammation

de Leon J, Ruan CJ, Verdoux H, Wang C.

COVID-19 and Dysfunctional Endothelium: The Mexican Scenario

Alvarado-Moreno JA, Majluf-Cruz A.

Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?

Nawar T, Morjaria S, Kaltsas A, Patel D, Perez-Johnston R, Daniyan AF, Mailankody S, Parameswaran R.

COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons

Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G.

Mechanism of inflammatory response in associated comorbidities in COVID-19

de Lucena TMC, da Silva Santos AF, de Lima BR, de Albuquerque Borborema ME, de Azevêdo Silva J.

Impacts of immunosuppression and immunodeficiency on COVID-19: a systematic review and meta-analysis.

Gao Y, Chen Y, Liu M, Shi S, Tian J.

The underlying changes and predicting role of peripheral blood inflammatory cells in severe COVID-19 patients: a sentinel?

Sun DW, Zhang D, Tian RH, Li Y, Wang YS, Cao J, Tang Y, Zhang N, Zan T, Gao L, Huang YZ, Cui CL, Wang DX, Zheng Y, Lv GY.

COMPLEMENT ACTIVATION IN PATIENTS WITH COVID-19: A NOVEL THERAPEUTIC TARGET.

Cugno M, Meroni PL, Gualtierotti R, Griffini S, Grovetti E, Torri A, Panigada M, Aliberti S, Blasi F, Tedesco F, Peyvandi F.

Covid-19 management with inflammation resolving mediators? Perspectives and potential

Regidor PA.

The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic

Wan MT, Shin DB, Winthrop KL, Gelfand JM.

Clinical features and development of sepsis in patients infected with SARS-CoV-2: a retrospective analysis of 150 cases outside Wuhan, China.

Ren D, Ren C, Yao RQ, Feng YW, Yao YM.

Changes to calf bTB testing during Covid-19.

[No authors listed]

Covid-19: Cases of inflammatory syndrome in children surge after urgent alert.

Mahase E.

Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: we are not sure.

Honore PM, Mugisha A, Kugener L, Redant S, Attou R, Gallerani A, De Bels D.

COVID-19: room for treating T cell exhaustion?

Riva G, Nasillo V, Tagliafico E, Trenti T, Luppi M.

A Case of COVID-19 and Pneumocystis jirovecii Co-infection.

Menon AA, Berg DD, Brea EJ, Deutsch AJ, Kidia KK, Thurber EG, Polsky SB, Yeh T, Duskin JA, Holliday AM, Gay EB, Fredenburgh LE.

Understanding the cytokine storm during COVID-19: Contribution of preexisting chronic inflammation.

Tuberculosis, COVID-19 and migrants: preliminary analysis of deaths occurring in 69 patients from two cohorts.

Motta I, Centis R, D'Ambrosio L, García-García JM, Goletti D, Gualano G, Lipani F, Palmieri F, Sánchez-Montalvá A, Pontali E, Sotgiu G, Spanevello A, Stochino C, Tabernero E, Tadolini M, van den Boom M, Villa S, Visca D, Migliori GB.

FAVORABLE ANAKINRA RESPONSES IN SEVERE COVID-19 PATIENTS WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS.

Dimopoulos G, de Mast Q, Markou N, Theodorakopoulou M, Komnos A, Mouktaroudi M, Netea MG, Spyridopoulos T, Verheggen RJ, Hoogerwerf J, Lachana A, van de Veerdonk FL, Giamarellos-Bourboulis EJ.

COVID-19: is fibrosis the killer?

Co-infection with COVID-19 and Influenza A Virus in two died patients with Acute Respiratory Syndrome, Bojnurd, Iran.

Hashemi SA, Safamanesh S, Ghafouri M, Taghavi MR, Mohajeri Zadeh Heydari MS, Abad HNA, Zadeh-Moghadam HG, Amir A.

Modulation of immune crosstalk in COVID-19.

Salomé B, Mahmood Z.

COVID-19 and the role of chronic inflammation in patients with obesity.

Chiappetta S, Sharma AM, Bottino V, Stier C.

Practical aspects of targeting IL-6 in COVID-19 disease.

Calabrese C, Rajendram P, Sacha G, Calabrese L.

Co-infection with respiratory pathogens among COVID-2019 cases.

The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China.

An inflammatory profile correlates with decreased frequency of cytotoxic cells in COVID-19.

Bordoni V, Sacchi A, Cimini E, Notari S, Grassi G, Tartaglia E, Casetti R, Giancola L, Bevilacqua N, Maeurer M, Zumla A, Locatelli F, De Benedetti F, Palmieri F, Marchioni L, Capobianchi MR, D'Offizi G, Petrosillo N, Antinori A, Nicastri E, Ippolito G, Agrati C.

Interleukin-6 Receptor Antagonist Therapy to Treat SARS-CoV-2 Driven Inflammatory Syndrome in a Renal Transplant Recipient.

Allam SR, Dao A, Madhrira MM, Antiporta PB, Nair RR, Guiteau JJ, Reyad AI.

A Review: Does Complement or the Contact System Have a Role in Protection or Pathogenesis of COVID-19?

Maglakelidze N, Manto KM, Craig TJ.

A Review: Does Complement or the Contact System Have a Role in Protection or Pathogenesis of COVID-19?

Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.

Omarjee L, Janin A, Perrot F, Laviolle B, Meilhac O, Mahe G.

Decreased T cell populations contribute to the increased severity of COVID-19.

Liu R, Wang Y, Li J, Han H, Xia Z, Liu F, Wu K, Yang L, Liu X, Zhu C.

Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy).

Stroppa EM, Toscani I, Citterio C, Anselmi E, Zaffignani E, Codeluppi M, Cavanna L.

Targeting raised von Willebrand factor levels and macrophage activation in severe COVID-19: Consider low volume plasma exchange and low dose steroid.

Co-infection with Influenza A and COVID-19.

A Case of Coinfection with SARS-COV-2 and Cytomegalovirus in the Era of COVID-19.

The fight to end tuberculosis must not be forgotten in the COVID-19 outbreak.

Manyazewal T, Woldeamanuel Y, Blumberg HM, Fekadu A, Marconi VC.

Reply to Kesici et al. and Zeng et al.: Blocking the virus and reducing the inflammatory damage in COVID-19.

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Chen Z, Zhang X, Yang X.

Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients.

Yu HQ, Sun BQ, Fang ZF, Zhao JC, Liu XY, Li YM, Sun XZ, Liang HF, Zhong B, Huang ZF, Zheng PY, Tian LF, Qu HQ, Liu DC, Wang EY, Xiao XJ, Li SY, Ye F, Guan L, Hu DS, Hakonarson H, Liu ZG, et al.

Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity.

Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Ischemic Stroke.

Valderrama EV, Humbert K, Lord A, Frontera J, Yaghi S.

COVID-19 Associated Pulmonary Aspergillosis.

van Arkel ALE, Rijpstra TA, Belderbos HNA, van Wijngaarden P, Verweij PE, Bentvelsen RG.

Invasive pulmonary aspergillosis complicating COVID-19 in the ICU - A case report.

Prattes J, Valentin T, Hoenigl M, Talakic E, Reisinger AC, Eller P.

Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab.

Recognition and management of respiratory coinfection and secondary bacterial pneumonia in patients with COVID-19.

Wu CP, Adhi F, Highland K.

Cytokine storm and the prospects for immunotherapy with COVID-19.

Calabrese LH.

COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions.

Kirkcaldy RD, King BA, Brooks JT.

[Dynamic inflammatory response in a critically ill COVID-19 patient treated with corticosteroids].

Zhagn S, Li D, Chen H, Zheng D, Zhou Y, Chen B, Shi W, Lin R.

Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?

Panigrahy D, Gilligan MM, Huang S, Gartung A, Cortés-Puch I, Sime PJ, Phipps RP, Serhan CN, Hammock BD.

IL-6 may be a good biomarker for earlier detection of COVID-19 progression.

Wang C, Fei D, Li X, Zhao M, Yu K.

Avoiding hospital-related infections during the COVID-19 epidemic.

Ye J, Yang L, Xi X, Lin X, He D, Wang W.

COVID-19 and ECMO: the interplay between coagulation and inflammation-a narrative review.

Kowalewski M, Fina D, Słomka A, Raffa GM, Martucci G, Lo Coco V, De Piero ME, Ranucci M, Suwalski P, Lorusso R.

Prognostic Value of Leukocytosis and Lymphopenia for Coronavirus Disease Severity.

Huang G, Kovalic AJ, Graber CJ.

A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex.

Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, Hu G, Wang Z, Zheng F, Wang L.

Feasibility of Therapeutic Effects of the Cholinergic Anti-Inflammatory Pathway on COVID-19 Symptoms.

Mazloom R.

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.

Merad M, Martin JC.

Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series.

Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, Martin-Silva N, Justet A.

Author's reply to "To the editor - Is it really COVID-19 infection?

Chang D, Epstein LM.

Letter to the editor - Is it really COVID-19?

Betancor IH, Orozco Garduño JA, Juarez Prera RA, Ojeda FB.

SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE?

Rojas A, Gonzalez I, Morales MA.

Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: insights from ERS-COVID-19 study.

Li D, Chen Y, Liu H, Jia Y, Li F, Wang W, Wu J, Wan Z, Cao Y, Zeng R.

Cytokine Storm Drugs Move from CAR T to COVID-19.

[No authors listed]

IL-6 blockade treatment for severe COVID-19 in two patients with multiple myeloma.

Chaidos A, Katsarou A, Mustafa C, Milojkovic D, Karadimitris A.

COVID-19 Infection and Sickle Cell Disease: A UK Centre Experience.

McCloskey KA, Meenan J, Hall R, Tsitsikas DA.

COVID-19, chronic inflammatory respiratory diseases and eosinophils - Observationsfrom reported clinical case series.

Jesenak M, Banovcin P, Diamant Z.

Dealing with immune-mediated neuropathies during COVID-19 outbreak: practical recommendations from the task force of the Italian Society of Neurology (SIN), the Italian Society of Clinical Neurophysiology (SINC) and the Italian Peripheral Nervous System Association (ASNP).

Dubbioso R, Nobile-Orazio E, Manganelli F, Santoro L, Briani C, Cocito D, Tedeschi G, Di Lazzaro V, Fabrizi GM; SIN, SINC and ASNP..

Correction to: SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes.

Nikolich-Zugich J, Knox KS, Rios CT, Natt B, Bhattacharya D, Fain MJ.

Infection prevention and control (IPC) for novel coronavirus (COVID-19).

[No authors listed]

To alert co-infection of SARS-COV-2 and dengue virus in developing countries in the dengue-endemic area.

Wu D, Lu J, Liu Q, Ma X, He W.

Evaluation of COVID-19 RT-qPCR test in multi-sample pools.

Yelin I, Aharony N, Shaer Tamar E, Argoetti A, Messer E, Berenbaum D, Shafran E, Kuzli A, Gandali N, Shkedi O, Hashimshony T, Mandel-Gutfreund Y, Halberthal M, Geffen Y, Szwarcwort-Cohen M, Kishony R.

Longitudinal Change of SARS-Cov2 Antibodies in Patients with COVID-19.

Zhang G, Nie S, Zhang Z, Zhang Z.

Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing.

Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, Satta G, Cooke G, Holmes A.

COVID-19: a case for inhibiting IL-17?

Pacha O, Sallman MA, Evans SE.

Will helminth co-infection modulate COVID-19 severity in endemic regions?

Bradbury RS, Piedrafita D, Greenhill A, Mahanty S.

Impaired interferon signature in severe COVID-19.

Gruber C.

Considerations for STI Clinics during the COVID-19 pandemic.

Napoleon SC, Maynard MA, Almonte A, Cormier K, Bertrand T, Ard KL, Chan PA.

The many faces of the anti-COVID immune response.

Vardhana SA, Wolchok JD.

Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists.

Konig MF, Powell MA, Staedtke V, Bai RY, Thomas DL, Fischer NM, Huq S, Khalafallah AM, Koenecke A, Xiong R, Mensh B, Papadopoulos N, Kinzler KW, Vogelstein B, Vogelstein JT, Athey S, Zhou S, Bettegowda C.

Antibody responses to SARS-CoV-2 in patients with COVID-19.

Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, Liao P, Qiu JF, Lin Y, Cai XF, Wang DQ, Hu Y, Ren JH, Tang N, Xu YY, Yu LH, Mo Z, Gong F, Zhang XL, Tian WG, Hu L, Zhang XX, et al.

Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.

Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, Neimann A, Adhikari S, Hudesman D, Scher JU.

Should we try the antiinflammatory natural product, celastrol, for COVID-19?

Habtemariam S, Nabavi SF, Berindan-Neagoe I, Cismaru CA, Izadi M, Sureda A, Nabavi SM.

The trinity of COVID-19: immunity, inflammation and intervention.

Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP.

Neutralizing antibody response in mild COVID-19.

van der Heide V.

Covid-19: concerns grow over inflammatory syndrome emerging in children.

Mahase E.

Elevated Interleukin-6 and Severe COVID-19: A Meta-Analysis.

Aziz M, Fatima R, Assaly R.

Long-term Coexistence of SARS-CoV-2 with Antibody Response in COVID-19 Patients.

Wang B, Wang L, Kong X, Geng J, Xiao D, Ma C, Jiang XM, Wang PH.

COVID-19 in Tuberculosis patients: a report of three cases.

He G, Wu J, Shi J, Dai J, Gamber M, Jiang X, Sun W, Cai J.

COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.

Theoharides TC.

Decreased Influenza Incidence under COVID-19 Control Measures, Singapore.

Soo RJJ, Chiew CJ, Ma S, Pung R, Lee V.

Collateral Benefit of COVID-19 Control Measures on Influenza Activity, Taiwan.

Kuo SC, Shih SM, Chien LH, Hsiung CA.

Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X, Zhu Q, Liu L.

COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency.

Isidori AM, Arnaldi G, Boscaro M, Falorni A, Giordano C, Giordano R, Pivonello R, Pofi R, Hasenmajer V, Venneri MA, Sbardella E, Simeoli C, Scaroni C, Lenzi A.

How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review.

Minotti C, Tirelli F, Barbieri E, Giaquinto C, Donà D.

Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019.

Zhu Z, Cai T, Fan L, Lou K, Hua X, Huang Z, Gao G.

Incidence of coronavirus disease (COVID-19) and countries affected by malarial infections.

Ahmed AE.

A possible role for B cells in COVID-19?: Lesson from patients with Agammaglobulinemia.

Quinti I, Lougaris V, Milito C, Cinetto F, Pecoraro A, Mezzaroma I, Mastroianni CM, Turriziani O, Bondioni MP, Filippini M, Soresina A, Spadaro G, Agostini C, Carsetti R, Plebani A.

COVID-19: lambda interferon against viral load and hyperinflammation.

Andreakos E, Tsiodras S.

Neutrophil extracellular traps in COVID-19.

Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, Blair CN, Weber A, Barnes BJ, Egeblad M, Woods RJ, Kanthi Y, Knight JS.

Translating IL-6 biology into effective treatments.

Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T.

Covid-19: Keep essential malaria services going during pandemic, urges WHO.

Thornton J.

The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia.

Li H, Chen K, Liu M, Xu H, Xu Q.

COVID-19 in cardiac arrest and infection risk to rescuers: a systematic review.

Couper K, Taylor-Phillips S, Grove A, Freeman K, Osokogu O, Court R, Mehrabian A, Morley PT, Nolan JP, Soar J, Perkins GD.

Endothelial cell infection and endotheliitis in COVID-19.

Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H.

COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome.

Hirano T, Murakami M.

Does high cardiorespiratory fitness confer some protection against pro-inflammatory responses after infection by SARS-CoV-2?

Zbinden-Foncea H, Francaux M, Deldicque L, Hawley JA.

Immunomodulators and immunosuppressants in the era of SARS-CoV-2 - could laboratory tests be the missing link?

Alpalh√£o M, Filipe P.

Is Low Alveolar Type II Cell SOD3 in the Lungs of Elderly Linked to the Observed Severity of COVID-19?

Abouhashem AS, Singh K, Azzazy HM, Sen CK.

Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome.

Quartuccio L, Semerano L, Benucci M, Boissier MC, De Vita S.

Carpal Fracture and COVID-19 Infection: Observation from Thailand.

Joob B, Wiwanitkit V.

Role of thymopoiesis and inflamm-aging in COVID-19 phenotype.

Scarpa R, Costa L, Del Puente A, Caso F.

Bacterial and fungal infections in COVID-19 patients: A matter of concern.

Zhou P, Liu Z, Chen Y, Xiao Y, Huang X, Fan XG.

Global Spread of Coronavirus Disease 2019 and Malaria: An Epidemiological Paradox in the Early Stage of A Pandemic.

Napoli PE, Nioi M.

The immunological case for staying active during the COVID-19 pandemic.

Simpson RJ, Katsanis E.

Weathering the cytokine storm in susceptible patients with severe SARS-CoV-2 infection.

Lipworth B, Chan R, Lipworth S, RuiWen Kuo C.

Surgical Infection Society Guidance for Operative and Peri-Operative Care of Adult Patients Infected by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).

Heffernan DS, Evans HL, Huston JM, Claridge JA, Blake DP, May AK, Beilman GS, Barie PS, Kaplan LJ.

Critically ill SARS-CoV-2-infected patients are not stratified as sepsis by the qSOFA.

Ferreira M, Blin T, Collercandy N, Szychowiak P, Dequin PF, Jouan Y, Guillon A.

Invasive fungal diseases during COVID-19: We should be prepared.

Gangneux JP, Bougnoux ME, Dannaoui E, Cornet M, Zahar JR.

Severe COVID-19 infection associated with endothelial activation.

Escher R, Breakey N, Lämmle B.

A severe case with co-infection of SARS-CoV-2 and common respiratory pathogens.

Ou X, Zhou L, Huang H, Lin Y, Pan X, Chen D.

Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies.

Zhao M.

Cytokine release syndrome in severe COVID-19.

Moore BJB, June CH.

Harnessing CAR T Cell Insights to Develop Treatments for Hyperinflammatory Responses in COVID-19 patients.

Agarwal S, June CH.

Thromboinflammation and the hypercoagulability of COVID-19.

Connors JM, Levy JH.

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients.

Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, Men D, Huang Q, Liu Y, Yang B, Ding J, Li F.

COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs.

Tufan A, Avanoğlu Güler A, Matucci-Cerinic M.

COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

Schett G, Sticherling M, Neurath MF.

Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19.

Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, Ferraz da Silva LF, Pierre de Oliveira E, Nascimento Saldiva PH, Mauad T, Marcia Negri E.

Venous thromboembolism in COVID-19 patients.

Porfidia A, Pola R.

On the alert for cytokine storm: Immunopathology in COVID-19.

Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, Caricchio R, Mahmud S, Hazen MM, Halyabar O, Hoyt KJ, Han J, Grom AA, Gattorno M, Ravelli A, de Benedetti F, Behrens EM, Cron RQ, Nigrovic PA.

The Imperfect Cytokine Storm: Severe COVID-19 with ARDS in Patient on Durable LVAD Support.

Chau VQ, Oliveros E, Mahmood K, Singhvi A, Lala A, Moss N, Gidwani U, Mancini DM, Pinney SP, Parikh A.

Pathogenic Priming Likely Contributes to Serious and Critical Illness and Mortality in COVID-19 via Autoimmunity.

Lyons-Weiler J.

Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses.

Raoult D, Zumla A, Locatelli F, Ippolito G, Kroemer G.

Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment.

Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X, Chen L, Gao H, Lu X, Yu L, Dai X, Xiang C, Li L.

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

Liu B, Li M, Zhou Z, Guan X, Xiang Y.

SARS-COV-2 infection is likely to be androgen mediated.

Wambier CG, Goren A.

COVID-19 can present with a rash and be mistaken for Dengue

: Petechial rash in a patient with COVID-19 infection.

COVID-19, syphilis and biologic therapies for psoriasis and psoriatic arthritis: A word of caution

.

Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19.

Liu Z, Long W, Tu M, Chen S, Huang Y, Wang S, Zhou W, Chen D, Zhou L, Wang M, Wu M, Huang Q, Xu H, Zeng W, Guo L.

Cytokine Storm in COVID-19 and Treatment.

Ye Q, Wang B, Mao J.

Inflammatory Response Cells During Acute Respiratory Distress Syndrome in Patients With Coronavirus Disease 2019 (COVID-19).

Zhang Y, Gao Y, Qiao L, Wang W, Chen D.

Good IgA bad IgG in SARS-CoV-2 infection?

Béné MC, de Carvalho M, Eveillard M, Lebri Y.

COVID-19 and dengue fever: A dangerous combination for the health system in Brazil.

Lorenz C, Azevedo TS, Chiaravalloti-Neto F.

Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats.

Malavolta M, Giacconi R, Brunetti D, Provinciali M, Maggi F.

Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients.

Sawalha AH, Zhao M, Coit P, Lu Q.

Harnessing Innate Immunity to Eliminate SARS-CoV-2 and Ameliorate COVID-19 Disease.

Golonka RM, Saha P, Yeoh BS, Chattopadhay S, Gewirtz AT, Joe B, Vijay-Kumar M.

Handling and Processing of Blood Specimens from Patients with COVID-19 for Safe Studies on Cell Phenotype and Cytokine Storm.

Cossarizza A, Gibellini L, De Biasi S, Lo Tartaro D, Mattioli M, Paolini A, Fidanza L, Bellinazzi C, Borella R, Castaniere I, Meschiari M, Sita M, Manco G, Clini E, Gelmini R, Girardis M, Guaraldi G, Mussini C.

Co-infection of Coronavirus Disease 2019 and Influenza A: A Report from Iran.

Khodamoradi Z, Moghadami M, Lotfi M.

COVID-19 and dengue, co-epidemics in Ecuador and other countries in Latin America: Pushing strained health care systems over the edge.

Navarro JC, Arrivillaga-Henríquez J, Salazar-Loor J, Rodriguez-Morales AJ.

Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome.

Adam Monteagudo L, Boothby A, Gertner E.

Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19.

Ma J, Xia P, Zhou Y, Liu Z, Zhou X, Wang J, Li T, Yan X, Chen L, Zhang S, Qin Y, Li X.

C-reactive protein levels in the early stage of COVID-19.

Wang L.

Celebrating TB day at the time of COVID-19.

Alagna R, Besozzi G, Codecasa LR, Gori A, Migliori GB, Raviglione M, Cirillo DM.

Infectious diseases in children and adolescents in China: analysis of national surveillance data from 2008 to 2017.

Dong Y, Wang L, Burgner DP, Miller JE, Song Y, Ren X, Li Z, Xing Y, Ma J, Sawyer SM, Patton GC.

Cytokine storms in COVID-19 cases?

Tveito K.

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.

Wu D, Yang XO.

Functional exhaustion of antiviral lymphocytes in COVID-19 patients.

Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, Xu Y, Tian Z.

Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients.

Zheng HY, Zhang M, Yang CX, Zhang N, Wang XC, Yang XP, Dong XQ, Zheng YT.

COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?

Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, Antinori S, Galli M.

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19).

Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang L, Han L, Dang S, Xu Y, Yang Q, Xu S, Zhu H, Xu Y, Jin Q, Sharma L, Wang L, Wang J.

COVID-19: consider cytokine storm syndromes and immunosuppression.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK..

Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.

Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, Kritas SK.

Dysregulation of immune response in patients with COVID-19 in Wuhan, China.

Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS.

Harnessing the immune system via FcγR function in immune therapy: a pathway to next-gen mAbs.

Chenoweth AM, Wines BD, Anania JC, Mark Hogarth P.

Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection.

Bermejo-Martin JF, Almansa R, Menéndez R, Mendez R, Kelvin DJ, Torres A.

Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools.

Fu Y, Cheng Y, Wu Y.

[Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies].

Chen C, Zhang XR, Ju ZY, He WF.

Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic.

Prompetchara E, Ketloy C, Palaga T.

Coronavirus infections and immune responses.

Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, Pan P, Wang W, Hu D, Liu X, Zhang Q, Wu J.

Emerging Viruses without Borders: The Wuhan Coronavirus.

Liu SL, Saif L.